Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation
Sponsor: Bausch Health Americas, Inc.
A PHASE4 clinical study on Opioid-Induced Constipation, this trial is completed. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Feb 2017 — Mar 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
- Progenics Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .